Single-Ascending Dose Study of JK07 in Subjects With HFpEF
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess
JK07 in adult subjects with heart failure with preserved ejection fraction.